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19.1 Depression and Antidepressants  
 
19.1.1 Depression 
Depression is described in the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV-TR) as a “mood disorder”, characterized by extreme or prolonged 
disturbance of mood, including sadness, lack of interest in or inability to experience pleasure, 
feelings of worthlessness and guilt, physical symptoms such as agitation, fatigue, insomnia 
and appetite changes, and often anxiety (American Psychiatric Association, 2004). In 
Australia, diagnosis of depression is made on the basis of a clinical interview using the DSM-
IV-TR criteria. The symptoms of depression may last four months or more if left untreated. 
In many cases functioning returns to normal after this, however in some cases symptoms 
linger. Recurring depressive episodes can lead to major depressive disorder. 
 
19.1.2 Neurochemistry of Depression and the Monoamine Theory 
The major neurotransmitters thought to be involved in depression are the monoamines, most 
likely noradrenaline and serotonin. 
 
Serotonin and noradrenaline are diffusely projecting neurotransmitters in the central nervous 
system, projecting from the brainstem raphe nuclei and locus coeruleus, respectively, to key 
brain regions such as the prefrontal cortex, limbic system and hypothalamus. Consequently, 
these neurotransmitters regulate behaviours such as cognition, vigilance, emotion and stress 
responses. 
 
The ‘monoamine theory of depression’ was first postulated in 1965 to suggest that depression 
is caused by a functional deficit of monamines in specific brain regions. This claim was based 
on pharmacological evidence that reserpine (from Rauwolfia serpentina) disrupts monoamine 
storage and causes depression, and that known antidepressant drugs augment the monoamine 
systems to increase available transmitters and ameliorate symptoms of depression. 
Nevertheless, monoamine levels are augmented straight away while the symptoms of 
depression take weeks to diminish. Moreover, it is shown that the delayed therapeutic effect 
of antidepressants coincides with monoamine receptor downregulation. 
 
The monoamine theory was thus revised in the 1980’s to suggest that the 
hyponoradrenergic/hyposerotoninergic state that is postulated to occur in depression leads to 
hypperresponsiveness of the adrenergic and serotoninergic receptors in certain parts of the 
brain. Accordingly, the action of antidepressants is to increase synaptic levels of 
noradrenaline and serotonin to normal, while downregulating “hyperresponsive” receptors to 
reinstate normal neuronal activities, accounting for the delayed therapeutic action of these 
drugs. 
 
19.1.3 Antidepressant Indications and Drug Classes 
Antidepressant drugs are primarily indicated for major depression, in treatment of episodes 
and prevention of relapse. They may also be prescribed for atypical depression, post-natal 
depression, depression related to a medical illness or schizophrenia, pain, and anxiety 
disorders. Antidepressants are often given to sufferers of anxiety disorders due to the 
numerous overlapping symptoms, and because current anxiolytics such as benzodiazepines 
show dependence liability and can impair learning and memory. 
 
Drugs currently used in Australia to treat depression fall into a number of major classes. The 
first antidepressant drugs to be synthesized were the tricyclic antidepressants (TCAs; 
imipramine being the prototype). Following TCAs were the irreversible monoamine oxidase 
inhibitors (MAOIs e.g. phenelzine), selective serotonin reuptake inhibitors (SSRIs; eg: 
fluoxetine), and serotonin-noradrenaline reuptake inhibitors (SNRIs; venlafaxine) and 
reversible inhibitor of monoamine oxidase A (RIMA; moclobemide).  
 
19.1.4 General Considerations with the use of Antidepressants 
Initial antidepressant drug therapy follows “start low, go slow”, the lowest dose is usually 
administered first and gradually increased as needed. Abrupt cessation of these drugs 
generally leads to withdrawal effects, which can be quite alarming with some classes such as 
the SSRIs, thus gradual weaning over weeks to months is recommended. A combination of 
antidepressant drugs is not recommended, it does not improve clinical efficacy and provides 
the opportunity for major drug-drug interactions.  A number of studies have suggested that 
antidepressant drugs may increase suicide risk when first taken. This is often because 
improvement does not occur in the first few weeks, which may worsen depression and 
suicidality. As a result, close monitoring of at-risk patients must occur during this period. 
Antidepressant drugs are generally administered for 4-6 months, as this timeframe has shown 
to improve symptoms of depression and reduce relapse, however some sufferers of 
depression remain continuously medicated. 
 
19.1.5 Tricyclic Antidepressants 
The tricyclic antidepressants (TCAs) are so named for their characteristic three-ringed 
molecular core. These drugs do not produce euphoria or dependence, and in depressed 
individuals they elevate mood, improve physical activity, appetite and sleep, and reduce 
rumination. The short term mechanism of action of all TCAs is blockade of presynaptic 
noradrenaline and serotonin high affinity reuptake transporters, which effectively increases 
availability of noradrenaline and serotonin in the synapse to act on pre- and post-synaptic 
noradrenergic and serotoninergic receptors. After many weeks of administration, tricyclic 
-adrenoceptors and 5-HT2 receptors, reducing the number and 
activity of these receptors. The time- -adrenoceptors is in keeping 
with the delayed therapeutic effect. Postsynaptic 5-HT1 receptors in the hippocampus are also 
increased with long- 2-adrenoceptors 
and 5-HT1 autoreceptors, which control noradrenaline and serotonin release, are 
downregulated, facilitating release of these neurotransmitters. 
 
TCAs also block muscarinic acetylcholine, histamine and serotonin (5-HT2, 5-HT3) receptors 
at therapeutic doses, leading to a number of side/adverse effects. These side effects include 
blurred vision, dry mouth, constipation, urinary retention, drowsiness, restlessness, insomnia, 
nausea, anorexia, diarrhoea, and disturbances of libido and potency. Most importantly, TCAs 
may cause adverse cardiovascular effects including hypotension, tachycardia and 
arrhythmias. These may become fatal in overdose through cardiotoxicity, and make the use of 
TCAs dangerous since the narrow therapeutic index allows for a relatively easy overdose. 
 
19.1.6 Monoamine Oxidase Inhibitors 
The monoamine oxidase inhibitors (MAOIs) fall into two categories, the irreversible non-
selective MAOIs (phenelzine) which bind covalently to both MAO-A and MAO-B, and the 
reversible inhibitor of MAO-A (moclobemide) which binds selectively to MAO-A. In 
depressed individuals their efficacy is similar to TCAs, although MAOIs are possibly more 
effective for atypical depression. These drugs inhibit the activity of monoamine oxidase 
enzymes (which function to maintain low cytoplasmic monoamine concentrations), 
preventing breakdown of the monoamines. This increase in the cytoplasmic pool of 
monoamines, without affecting vesicular stores, increases spontaneous leakage of 
monoamines into the synapse and extracellular space. Consequently, noradrenaline and 
serotonin (and dopamine) availability is enhanced to act on pre- and post-synaptic receptors. 
After many weeks of administration, MAOIs -adrenoceptors and 5-HT2 
receptors, similar to TCAs. They also consistently downregulate α1-adrenoceptors and 
postsynaptic 5-HT1 2-
adrenoceptors and 5-HT1 autoreceptors, which control noradrenaline and serotonin release, 
thus monoamine release is facilitated. 
 
MAOIs cause fewer side/adverse effects than TCAs. They still have a propensity to cause 
nausea, insomnia, hypotension, dizziness, and disturbances of libido and potency, however 
they cause fewer anticholinergic side effects (dry mouth, blurred vision, urinary retention 
etc.). Nonetheless the usefulness of irreversible MAOIs has been limited by their interaction 
with sympathomimetic agents such as tyramine in foods. This can create a hypertensive 
crisis, the so-called “cheese-reaction”, which may be fatal and requires strict adherence to 
dietary guidelines. The RIMA, moclobemide, is much safer than the irreversible MAOIs due 
to its selectivity for MAO-A. 
 
19.1.7 Selective Serotonin Reuptake Inhibitors 
Selective serotonin reuptake inhibitors (SSRIs) demonstrate similar efficacy to TCAs in 
treating moderate depression, but possibly less efficacy in treating severe depression. These 
drugs have been shown to be very effective in reducing anxiety and agitation associated with 
depression. At therapeutic doses SSRIs demonstrate 50-fold selectivity for serotonin 
transporters over noradrenaline transporters. Owing to this highly selective blockade of the 
serotonin transporters, SSRIs increase levels of serotonin in the synapse. With longer-term 
administration, SSRIs downregulate postsynaptic 5-HT2 receptors and, like TCAs, increase 
sensitivity of postsynaptic 5-HT1 receptors in the hippocampus. Similarly to TCAs and 
MAOIs, SSRIs decrease the sensitivity of presynaptic 5-HT1 autoreceptors, thus facilitating 
serotonin release. In this way, SSRIs enhance serotoninergic transmission by re-establishing 
normal firing rate, increasing serotonin output, and increasing postsynaptic (5-HT1) receptor 
sensitivity in the hippocampus. 
 
Unlike TCAs, SSRIs have little affinity for cholinergic and histaminergic receptors, and it is 
this purity of effect that has led to their popularity, owing to reduction in side effects. 
Nonetheless these drugs produce numerous 5-HT receptor-mediated side effects including 
nausea and vomiting, diarrhoea, agitation, insomnia, tremor, and disturbances of potency and 
libido. Further, a combination of SSRIs with other drugs that enhance serotoninergic 
transmission may lead to ‘serotonin syndrome’ resulting from serotonin toxicity. SSRIs are 
less dangerous in overdose than TCAs and MAOIs due to the lack of cardiotoxicity and their 
large therapeutic index. 
 
19.1.8 Noradrenaline and Serotonin Reuptake Inhibitor 
Venlafaxine is an example of a serotonin-noradrenaline reuptake inhibitor (SNRI). This drug 
acts similarly to TCAs and SSRIs by blocking noradrenaline and/or serotonin reuptake, 
however venlafaxine is highly selective for the transporters, thus obviating numerous side 
effects related to administration of TCAs or SSRIs.  
 
19.1.10 Long Term Adaptive Changes with Antidepressants 
The net effect of chronic treatment with antidepressant drugs is enhancement of 
monoaminergic function. Irrespective of the underlying transmitter imbalance (which remains 
to be well characterized), it seems antidepressant drugs optimize monoamine levels by 
facilitating release and restore receptor sensitivities to normal or permit preferred receptor 
actions. Increasing monoamine levels may be the first step, creating a complex sequelae of 
cellular and molecular changes. The time course of these long term adaptive changes is 
paralleled by mood changes. 
  
19.2 Psychosis, Schizophrenia and Antipsychotic Drugs  
 
19.2.1 Psychosis and Schizophrenia 
Psychosis is a phenomenon that is associated with a number of disorders, including bipolar 
affective disorder (manic depression), drug withdrawal, and most evidently, schizophrenia. 
The drugs used to treat schizophrenia are also used to treat other disease entities manifesting 
in psychosis, which is why they are referred to as antipsychotics rather than 
antischizophrenics.  
 
Schizophrenia itself is in fact a syndrome, characterised by a number of symptoms which 
different sufferers demonstrate to different extents.  The symptoms have been grouped into 
three major dimensions; positive symptoms reflecting an excess or distortion of normal 
thinking, negative symptoms reflecting a loss or reduction in normal behaviours, and 
cognitive symptoms reflecting a deficit in some cognitive behaviours such as attention and 
working memory. Positive symptoms are akin to the usual “psychosis”, and may manifest as 
delusions, hallucinations, and disorganised thought and speech. Negative symptoms may 
show as blunted emotional responses, diminution in goal directed behaviours, and lack of 
interest in or inability to experience pleasure. Schizophrenia is characterized as a thought 
disorder, although depression may occur. The symptoms of schizophrenia can be extremely 
distressing, and cause major disruption to social and occupational functioning. The average 
age of onset is adolescence or early adulthood, and course is often chronic, rarely remitting, 
and usually improved through pharmacological intervention.  
 
The cause of schizophrenia remains unknown, but current evidence suggests it involves a 
gene-environment interaction. The collective effect of numerous common genetic variants 
interacts with environmental factors, which are moderated by the genes, causing alterations to 
brain development and, in time, information processing. Environmental factors that have 
been identified include pre-, peri-, and post-natal effects (stress, malnutrition, infection, 
obstetric complication), early-life stress (trauma, separation), frequent drug use (cannabis, 
amphetamines), and stressful life events (migration, illness, adversity etc.). 
 
19.2.2 Neurochemistry of Psychosis and the Dopamine Theory 
The history of dopamine’s involvement in psychosis and schizophrenia is long, and only the 
most recent theories will be considered here, since the early dopamine theories of 
schizophrenia did not withstand testing. The discovery that all early antipsychotics were 
antagonists of dopamine D2 receptors pointed to a role for dopamine in psychosis. It was 
further shown that clinical efficacy of antipsychotics is consistently achieved when D2 
receptor occupancy reaches at least 60% (40-80%), and is correlated linearly with their D2 
receptor affinity. 
 
Davis and colleagues (1991) theorised that reduced dopamine release in prefrontal cortex 
causes negative symptoms of schizophrenia and leads to increased dopamine release in 
subcortical regions (specifically the ventral striatum containing the nucleus accumbens) 
which causes positive symptoms. While this theory accounted for available data and 
integrated knowledge of brain regions and dopamine receptor distributions, clinical evidence 
is still limited, most of the evidence comes from animal studies. Howes and Kapur (2009) 
modified the theory to suggest that increased presynaptic dopamine function in the ventral 
striatum is the ‘final common pathway’ for psychosis. This theory is supported by clinical 
evidence of elevated presynaptic dopamine, dopamine release, and dopamine receptor density 
in the ventral striatum during psychosis, and animal models showing genetic and 
environmental factors contribute to this. It is thought that elevated dopamine transmission in 
the ventral striatum influences aberrant motivational salience to otherwise innocuous stimuli 
(people, objects and actions), and psychosis arises from an effort to construct plausible 
explanations. 
 
While the role of dopamine is necessary in schizophrenia, it is not sufficient. Dopamine 
dysregulation no doubt accounts for psychosis, but it is thought multiple transmitter systems, 
including GABA and glutamate, underlie the negative and cognitive symptoms.  Researchers 
have suggested dopamine forms the converging pathway in schizophrenia, not the primary 
abnormality, and that deficiencies in one or more other neurotransmitter systems which 
modulate domapine leads to the dopaminergic overactivity. 
 
19.2.3 Antipsychotic Drug Indications and Drug Classes  
Antipsychotics are indicated in the treatment of psychosis and symptoms of schizophrenia, 
and prevention of relapse. 
 
Antipsychotic drugs are divided into two major classes. The first is the ‘typical’ or ‘first 
generation’ antipsychotics. Chlorpromazine was the prototype, a phenothiazine drug 
originally developed as an antihistamine agent. Subsequent to chlorpromazine, numerous 
typical antipsychotics were developed, forming the only types available until the late 1980’s. 
The second class is the ‘atypical’ or ‘second generation’ antipsychotics. The first of these 
developed was clozapine, found to be ‘atypical’ in that at therapeutic doses it was far less 
likely to cause adverse motor and hormone side effects seen with the ‘typical’ antipsychotics. 
Based on clozapine’s chemical structure and receptor binding properties, numerous atypical 
antipsychotics have been developed which now offer first line therapy in the treatment of 
schizophrenia. 
 
19.2.4 Antipsychotic Mechanisms of Action 
Antipsychotic drugs are potent dopamine D2 receptor antagonists. D2 autoreceptors control 
release of dopamine from presynaptic neurons. By blocking elevated ventral striatal 
dopamine release, antipsychotics ameliorate dopamine dysregulation. Animal studies have 
shown that antipsychotics initially increase (due to D2 receptor autoreceptor blockade) and 
then decrease midbrain dopaminergic neuron activity in the substantia nigra and ventral 
tegmental area (containing dopaminergic cell bodies), and dopamine release in regions where 
dopamine cells project to, such as the ventral striatum and prefrontal cortex. This decreased 
dopaminergic activity occurs as D2 receptors upregulate due to chronic blockade, and the 
time course of this increased receptor expression parallels the delayed therapeutic effect of 
the drugs.  
 
The therapeutic effects of antipsychotics, as already mentioned, are thought to occur via the 
mesocortical/mesolimbic dopamine pathway (ventral tegmental area to prefrontal cortex and 
ventral striatum). The side effects commonly seen with antipsychotics are thought to occur 
through antagonism of the nigrostriatal pathway (substantia nigra to caudate/putamen), where 
movement disorders result, and the tuberoinfundibular pathway (hypothalamus to pituitary), 
which lead to endocrine abnormalities 
 
19.2.6 Typical Antipsychotics (First Generation) 
Typical antipsychotics comprise a number of different types of chemicals, including 
chlorpromazine, and haloperidol).  Both of these drugs ameliorate the positive (psychotic) 
symptoms of schizophrenia but have little effect on negative and cognitive symptoms. These 
drugs, in addition to being potent D2 receptor antagonists demonstrating up to 80% 
occupancy at therapeutic doses, show moderate potency at α-adrenergic, 5-HT2, muscarinic 
acetylcholine, and histamine receptors at therapeutic doses (except haloperidol which is 
highly selective for D2 receptors).  
 
As they block many receptors, the typical antipsychotics, have numerous anticholinergic (dry 
mouth, blurred vision, constipation), antihistaminergic (sedation, drowsiness), adrenergic 
(cardiac side effects, hypotension) and serotoninergic (weight gain) side effects. The most 
severe side effects with these drugs, however, occur through their target dopamine receptors. 
By blocking dopamine transmission in the nigrostriatal pathway, antipsychotic drugs cause 
movement disorders such as tardive dyskinesia (loss of voluntary control of movements 
which is debilitating and may not remit following drug cessation), parkinsonism (tremor, 
shuffling gait, cogwheel rigidity etc.), disordered muscle tone and motor restlessness. 
Blocking dopamine transmission in the tuberinfundibular pathway causes elevated prolactin 
secretion from the pituitary gland, leading to enlarged breasts, weight gain, erectile 
dysfunction and menstrual irregularities. The extent and severity of side effects incurred with 
typical antipsychotic drugs limits their effectiveness as patients are less likely to comply with 
treatment. 
 
19.2.6 Atypical Antipsychotics (Second Generation) 
Atypical antipsychotics are very different chemicals to typical antipsychotics, with different 
receptor binding profiles. The prototype of this group was clozapine, which ameliorates the 
positive symptoms of schizophrenia, and some are quite effective on the negative and 
cognitive symptoms as well. Clozapine has proven most effective, however it is not first line 
therapy owing to its liability to cause agranulocytosis, myocarditis and cardiomyopathy in 
vulnerable individuals. It is reserved for individuals who fail to respond to other drugs, with 
close monitoring.  
 
Most atypical antipsychotics are dopamine D2 receptor antagonists. These drugs occupy 40-
60% of D2 receptors at therapeutic doses. Many of the atypical antipsychotics have high 
affinity for 5-HT2 receptors.  It is considered that the ratio of D2:5-HT2 receptor occupancy 
provides additional therapeutic features of atypical antipsychotics, and reduces their liability 
to cause motor and endocrine side effects, thus making them more tolerable, which improves 
compliance. Clozapine and olanzapine, currently the most effective antipsychotics, also 
show high affinity for dopamine D4 receptors. 
 
Whilst atypical antipsychotics produce fewer side effects than the typical antipsychotics, 
their use has lead to the emergence of another insidious side effect, metabolic syndrome. 
These drugs can cause weight gain, hyperglycaemia and elevated triglycerides, which 
increase risk of obesity, cardiovascular disease and diabetes mellitus. Thus, although these 
drugs appear to be an improvement on the typical antipsychotics, they do not escape 
limitations. 
 
 
19.3 Anxiety and Anxiolytics 
 
19.3.1 Fear, Anxiety and Anxiety Disorders 
Fear and anxiety are adaptive responses to aversive stimuli (eg: danger, pain, noxious 
conditions) that facilitate survival. Fear represents an immediate, often innate, response to 
threatening stimuli, but can also be learnt (conditioned) so that specific stimuli are predicted 
to be associated with danger, pain or harm. Anxiety is a state of anticipation of danger, 
elicited by less specific cues, and is learnt. It is characterized by vigilance, physiological 
autonomic arousal and subjective distress. Normal fear and anxiety behaviours include 
avoidance, escape or defense.  
 
Anxiety disorders arise when: normal fearful or anxious behaviours become exaggerated or 
prolonged, or occur in the absence of any real threat; anticipation of a feared event or object 
becomes distressing; or increased salience is given to usually innocuous stimuli so that they 
come to be perceived as threatening. Precipitating factors may be external (e.g. situation, 
object) or internal (such as catastrophic cognitions or rationalizations, recall of stressful 
experiences, or physiological autonomic arousal). DSM-IV-TR categorises anxiety disorders 
into a number of subtypes, including social phobia, specific phobias, panic disorder, 
obsessive-compulsive disorder, post-traumatic stress disorder, and generalized anxiety 
disorder. Each of these has unique features, however the common characteristics include 
somatic (motor tension, trembling, palpitations, restlessness, sleep disturbances), emotional 
(distress, fear and anxiety) and cognitive (hypervigilance, derealization, negative self-
evaluation) features. For clinical diagnosis according to DSM-IV-TR, the anxiety must 
interfere significantly with social and occupational functioning, or this interference causes 
significant distress. 
 
19.3.2 Neurochemistry of Anxiety 
Fear and anxiety activate many brain circuits, including those involved in sensory input 
(thalamus and sensory cortex), contextual memory (hippocampus), conditioned emotional 
responses and fear responses (central nucleus of the amygdala), activation of hypothalamic-
pituitary-adrenal (HPA) axis (hypothalamus) and cortisol release, salience and conditioned 
avoidance (striatum), arousal and vigilance (locus coeruleus and raphe nuclei) and cognition 
and executive functions (neocortex, especially prefrontal cortex). Research has shown that 
the central nucleus of the amygdala, mediates certain responses to immediate aversive stimuli 
while other limbic structures such as the bed nucleus of the stria terminalis and 
septohippocampal regions are also implicated in the more contextual, chronic and general 
stimuli involved in the genesis of anxiety. Anxiety disorder sufferers appear to demonstrate 
hyperresponsive amygdala circuitry (involved in fear responses) and decreased prefrontal 
cortex activity that usually functions to suppress fear and anxiety. 
 
The neurotransmitters and hormones implicated in fear and anxiety include γ-aminobutyric 
acid (GABA), serotonin, noradrenaline, adrenaline and corticotropin releasing factor (CRF). 
The involvement of these transmitter substances will be further outlined in subsequent 
sections. 
 
19.3.3 Anxiolytic Drug Indications and Drug Classes 
Anxiolytic drugs act to reduce anxiety. Research has shown that different subtypes of anxiety 
disorders are best managed with different therapies, however the predominant therapies are 
benzodiazepines and antidepressants (such as the SSRIs). It is important to appreciate that 
benzodiazepines are used for a variety of reasons other than anxiolysis, including muscle 
relaxation, sedation and sleep, convulsions, and alcohol withdrawal. Similarly, some 
antidepressant drugs are very effective anxiolytics.  
 
Non-pharmacological interventions such as cognitive-behavioural therapy and fear extinction 
may also be highly effective in the treatment of anxiety disorders. Indeed, a combination of 
both psychological and pharmacological treatments is most efficacious.  
 
19.3.4 Benzodiazepines 
Benzodiazepines are allosteric modulators of the GABAA receptors. GABAA receptors are 
ligand-gated ion channels, gated by the amino acid transmitter, GABA. When activated, they 
conduct chloride ions, the net effect being a reduction in membrane excitability and inhibition 
of cell firing.  
 
These receptors are found in many brain regions such as the amygdala (including central 
nucleus), hippocampus, bed nucleus of the stria terminalis, striatum (dorsal and ventral), 
hypothalamus and prefrontal cortex. When GABA is bound, benzodiazepines increase the 
frequency of ion channel opening, thus increasing chloride conductance and the potency of 
GABA.  
 
Examples of benzodiazepines include diazepam, midazolam and temazepam.  These drugs 
are similar in their mechanism of action, however differ in their pharmacokinetics, such that 
some are much shorter-acting (e.g. midazolam) and some are much longer-acting (e.g. 
diazepam,). Shorter acting drugs may be useful for inducing or maintaining sleep, while 
longer acting are preferred for treatment of anxiety disorders.  
 
Benzodiazepines have the advantage of being rapid in onset (within hours) and are therefore 
very useful in treating acute anxiety states, such as panic disorder and phobias, and they are 
also useful in generalised anxiety disorder. Unfortunately, while being very effective 
anxiolytics, benzodiazepines have some unwanted side effects, including sedation, memory 
loss (amnesia) and dependence liability (they are addictive). Their tendency to cause 
drowsiness and confusion in elderly patients also negates their use in this demographic.  
 
Benzodiazepines interact with other depressants such as alcohol, making their use in 
combination dangerous as this enhances sedation, memory loss, and respiratory depression. 
Since they are potentially addictive, benzodiazepines are recommended for acute use, usually 
two weeks at a time, although in some cases chronic use is justified. The withdrawal 
syndrome from benzodiazepines can be quite severe, therefore gradual weaning is required. 
 
19.3.5 Antidepressants 
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, and more recently the 
serotonin-noradrenaline reuptake inhibitors (SNRIs, e.g. venlafaxine), are useful in the 
treatment of some anxiety disorders such as panic disorder, generalised anxiety disorder, 
obsessive-compulsive disorder and post-traumatic stress disorder. In fact, these drugs are 
suggested as first line therapy for many anxiety disorders, especially where chronic treatment 
is required.  
 
Monoamine oxidase inhibitors have been used for phobias, and some tricyclics 
antidepressants are indicated for panic disorder and post-traumatic stress disorder. The 
mechanisms of action and side effects of these drugs are outlined in an earlier section (20.1).  
 
The treatment resistance in roughly one third of individuals given antidepressants occurs not 
only in depression, but also with the use of antidepressants to treat anxiety. The variation in 
response to antidepressants is now thought to be due to pharmacogenetics.  
 19.3.6 Buspirone 
Buspirone is a 5-HT1A receptor partial agonist found to be somewhat useful in treatment of 
panic disorder and generalised anxiety disorder. 5-HT1A receptor activation usually inhibits 
release of neurotransmitters like serotonin from the raphe nuclei and noradrenaline from the 
locus coeruleus. Buspirone therefore partially blocks noradrenaline release, hence centrally-
mediated physiological arousal.  By partially blocking somatic 5-HT1A autoreceptors on 
raphe nuclei, buspirone also facilitates release of serotonin. The therapeutic effects, however, 
take days to weeks to occur, therefore must involve more complex mechanisms for anxiolytic 
action. Side effects of buspirone include dizziness, nausea, headache and restlessness, but it 
avoids the psychomotor impairment and dependence liability incurred with the use of 
benzodiazepines. 
 
